Boston Scientific To Acquire Axonics For About $3.7 Bln
In a groundbreaking move, Boston Scientific Corporation (NYSE: BSX) has recently announced its definitive agreement to acquire Axonics, Inc. (Nasdaq: NASDAQ:AXNX ), a pioneering medical technology company specializing in the development and commercialization of advanced devices to address urinary and bowel dysfunction. This strategic acquisition, valued at approximately $3.7 billion, positions Boston Scientific at the forefront of the rapidly growing sacral neuromodulation (SNM) therapy market, offering innovative solutions for patients suffering from overactive bladder (OAB) and fecal incontinence.
Axonics' Cutting-Edge Technology:
Axonics has made significant strides in the field of urology with its state-of-the-art Axonics R20TM and Axonics F15TM Systems. These systems, which utilize sacral neuromodulation therapy, have demonstrated meaningful improvement in patients' quality of life over a two-year period, with no serious device-related adverse events reported. The recent FDA approval for the fourth-generation Axonics R20 neurostimulator, a rechargeable SNM device with an impressive battery life of 20 years or more, further solidifies Axonics' position as a leader in the market.
Addressing a Growing Need:
The acquisition comes at a crucial time when an estimated 30 million adults in the United States aged 40 and older experience bothersome symptoms of overactive bladder, and 19 million adults suffer from fecal incontinence. These conditions significantly impact patients' quality of life, mental health, sleep, productivity, and social activities. Boston Scientific's move to integrate Axonics' portfolio into its offerings reflects a commitment to addressing these often-chronic conditions with cutting-edge solutions.
Strategic Implications for Boston Scientific:
Meghan Scanlon, Senior Vice President and President, Urology at Boston Scientific, expressed excitement about the acquisition, emphasizing the potential to strengthen the company's ability to serve urologists and expand access to care for patients. The entry into sacral neuromodulation represents a high-growth adjacency for Boston Scientific, with opportunities for further innovation and market expansion.
Financial Outlook and Impact:
Axonics is expected to deliver net revenue of approximately $366 million in 2023, marking a remarkable 34% growth over the prior fiscal year. Boston Scientific anticipates the transaction to be completed in the first half of 2024, subject to customary closing conditions. While the impact on Boston Scientific's adjusted earnings per share is expected to be immaterial in 2024, the acquisition is projected to be accretive thereafter, reflecting the long-term value and growth potential of Axonics' revenue profile.
Conclusion:
Boston Scientific's acquisition of Axonics marks a significant milestone in the medical technology landscape, with the potential to revolutionize the treatment of urinary and bowel dysfunction. As the companies join forces, the collaboration is poised to bring about innovative solutions, ultimately improving the lives of millions of individuals grappling with these challenging health conditions. The move underscores Boston Scientific's commitment to advancing healthcare through strategic partnerships and cutting-edge technologies.
